Literature DB >> 29560736

Evaluating Vasopressor Discontinuation Strategies in Patients With Septic Shock on Concomitant Norepinephrine and Vasopressin Infusions.

Nadine Musallam1, Diana Altshuler1, Cristian Merchan1, Bishoy Zakhary1, Caitlin Aberle1, John Papadopoulos1.   

Abstract

BACKGROUND: There is little data guiding clinicians on how to discontinue vasopressors among septic shock patients on concomitant norepinephrine (NE) and vasopressin (VP).
OBJECTIVE: To determine the incidence of hypotension within 24 hours of discontinuing NE (NE DC first) versus VP (VP DC first) first in septic shock patients.
METHODS: This retrospective study evaluated septic shock patients admitted to the medical intensive care unit (MICU) and surgical ICU (SICU) receiving concomitant NE and VP. Receipt of additional vasopressors, mixed shock states, expired or care withdrawn, and NE and VP discontinued simultaneously were exclusion criteria. The primary outcome was incidence of hypotension within 24 hours of first vasopressor discontinuation. Secondary outcomes included time to hypotension, hospital length of stay (LOS), ICU LOS, and ICU mortality.
RESULTS: A total of 80 patients were included (NE DC first [n = 35]; VP DC first [n = 45]), with a median age of 73 years and median modified Acute Physiology and Chronic Health Evaluation II and Sequential Organ Failure Assessment scores of 21 and 7, respectively. More patients in the NE DC first group were in the SICU (42.9% vs 20.0%; P = 0.048) with more intra-abdominal infections (40.0% vs 15.6%; P = 0.021) and fewer appropriate empirical antibiotics (62.9% vs 86.7%; P = 0.018). Hypotension within 24 hours of first agent discontinuation was higher in the VP DC first group (28.6% vs 62.2%; P = 0.004), with similar hospital LOS and ICU mortality. Multivariate analysis identified VP DC first as an independent predictor of hypotension (odds ratio = 7.2; CI = 2.3-22.7).
CONCLUSION: Among septic shock patients on concomitant NE and VP, discontinuation of VP first was associated with an increased incidence of hypotension; future prospective control trials are warranted.

Entities:  

Keywords:  discontinuation; hypotension; norepinephrine; septic shock; vasopressin; vasopressin deficiency

Mesh:

Substances:

Year:  2018        PMID: 29560736     DOI: 10.1177/1060028018765187

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  7 in total

1.  Impact of the Sequence of Norepinephrine and Vasopressin Discontinuation in Patients Recovering From Septic Shock.

Authors:  Benjamin E Bredhold; Shauna D Winters; John C Callison; Robert E Heidel; Lauren M Allen; Leslie A Hamilton
Journal:  Hosp Pharm       Date:  2018-12-05

2.  Norepinephrine in septic shock.

Authors:  Glenn Hernández; Jean-Louis Teboul; Jan Bakker
Journal:  Intensive Care Med       Date:  2019-01-10       Impact factor: 17.440

3.  Care Bundles plus Detailed Nursing on Mortality and Nursing Satisfaction of Patients with Septic Shock in ICU.

Authors:  Min Wang; Yan Zhang; Ailing Zhong; Fen Zhou; Haibo Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-23       Impact factor: 2.650

4.  Vasopressor Discontinuation Order in Septic Shock With Reduced Left Ventricular Function.

Authors:  Ashley Taylor; Timothy Jones; Christy Cecil Forehand; Susan E Smith; Hannah Dykes; Andrea Sikora Newsome
Journal:  J Pharm Pract       Date:  2021-05-12

5.  Weaning order of vasoactive drugs.

Authors:  Vilto Michels; Daisson José Trevisol
Journal:  Crit Care       Date:  2019-03-13       Impact factor: 9.097

6.  Effects of Collagen Antibacterial Functional Dressing plus Continuous Nursing on Lower Extremity Skin Injury Caused by Norepinephrine in Patients with Septic Shock.

Authors:  Xiaoxia Hu; Hongxia Wang; Yun Lin
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-18       Impact factor: 2.650

7.  Incidence of Hypotension after Discontinuation of Norepinephrine or Arginine Vasopressin in Patients with Septic Shock: a Systematic Review and Meta-Analysis.

Authors:  Jae Uk Song; Jonghoo Lee; Hye Kyeong Park; Gee Young Suh; Kyeongman Jeon
Journal:  J Korean Med Sci       Date:  2020-01-06       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.